Дисфункция почек при поступлении в блок кардиореанимации - фактор риска госпитальной летальности у больных с острым инфарктом миокарда с подъемом сегмента ST
Download
2. Томилина, Н. А. Проблема сердечно-сосудистых заболеваний при хронической почечной недостаточности / Н. А. Томилина, Г. В. Волгина, Б. Т. Бикбов, И. Г. Ким // Нефрол. и диализ. – 2003. – № 1. – С. 15–24.
3. Al-Ahmad, A. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction / A. Al-Ahmad, W. M. Rand, G. Manjunath et al. // J. Am. Coll. Cardiol. – 2001. – Vol. 38. – P. 955–962.
4. Garg, A. X. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I / A. X. Garg, W. F. Clark, R. B. Haynes, A. A. House // Kidney Int. – 2002. – Vol. 61. – P. 1486–1494.
5. Gibson, C. M. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality / C. M. Gibson, D. S. Pinto, S. A. Murphy et al. // J. Am. Coll. Cardiol. – 2003. – Vol. 42. – P. 1535–1543.
6. Go, A. S. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization / A. S. Go, G. M. Chertow, D. Fan et al. // N. Engl. J. Med. – 2004. – Vol. 351. – P. 1296–1305.
7. Goldberg, A. In-hospital and one-year mortality of patients who develop worsening renal function after acute ST-elevation myocardial infarction / A. Goldberg, H. Hammerman, S. Petcherski et al. // Circulation. – 2004. – Vol. 110. – P. III-391.
8. Jose, P. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction / P. Jose, H. Skali, N. Anavekar et al. // J. Am. Soc. Nephrol. – 2006. – Vol. 17. – P. 2886–2891.
9. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification // Am. J. Kidney Dis. – 2002. – Vol. 39 (Febr. Suppl. 1).
10. Keane, W. F. Renal protective effects of angiotensinconverting enzyme inhibition / W. F. Keane, B. E. Shapiro // Am. J. Cardiol. – 1990. – Vol. 65. – P. 49I–53.
11. Keith, D. S. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization / D. S. Keith, G. A. Nichols, C. M. Gullion et al. // Arch. Intern. Med. – 2004. – Vol. 164. – P. 659–663.
12. Marenzi, G. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty / G. Marenzi, M. Moltrasio, E. Assanelli et al. // Am. Heart J. – 2007. – Vol. 153. – P. 755–762.
13. Matsuda, H. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin / H. Matsuda, K. Hayashi, K. Arakawa // J. Am. Soc. Nephrol. – 1999. – Vol. 10. – P. 2272–2282.
14. Nohria, A. Cardiorenal interactions–insights form the ESCAPE trial / A. Nohria, V. Hasselblad, A. Stebbins et al. // J. Am. Coll. Cardiol. – 2007. – Vol. 51. – P. 1268–1274.
15. Ronco, C. Cardiorenal syndrome / C. Ronco, M. Haapio, A. A. House et al. // J. Am. Coll. Cardiol. – 2008. – Vol. 52. – P. 1527–1539.
16. Sarnak, M. J. Cardiovascular disease risk factors in chronic renal insufficiency / M. J. Sarnak, B. E. Coronado, T. Greene et al. // Clin. Nephrol. – 2002. – Vol. 57, № 5. – P. 327–335.
17. Sorensen, C. R. The prognostic importance of creatinine clearance after acute myocardial infarction / C. R. Sorensen, B. Brendorp, C. Rask-Madsen et al. // Eur. Heart J. – 2002. – Vol. 23. – P. 948–952.
18. Tokmakova, M. P. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study / M. P. Tokmakova, H. Skali, S. Kenchaiah et al. // Circulation. – 2004. – Vol. 110. – P. 3667–3673.
Abstract
Aim: to determine the relation of in-hospital mortality in acute myocardial infarction with ST elevation (STEMI) with glomerular filtration rate estimated by means of the four-component Modification of Diet in Renal Disease equation (eGFR) at admission to intensive care unit. In-hospital mortality among 342 patients with STEMI was analized. In the group with eGFR < 60 ml/min/1.73 m2 in-hospital mortality was significantly higher then in group with eGFRReferences
1. Сторожаков, Г. И. Поражение сердечно-сосудистой системы при хронической почечной недостаточности / Г. И. Сторожаков, Г. Е. Гендлин, Н. А. Томилина и др. // Рос. мед. журн. – 2005. – № 2. – С. 4–8.2. Томилина, Н. А. Проблема сердечно-сосудистых заболеваний при хронической почечной недостаточности / Н. А. Томилина, Г. В. Волгина, Б. Т. Бикбов, И. Г. Ким // Нефрол. и диализ. – 2003. – № 1. – С. 15–24.
3. Al-Ahmad, A. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction / A. Al-Ahmad, W. M. Rand, G. Manjunath et al. // J. Am. Coll. Cardiol. – 2001. – Vol. 38. – P. 955–962.
4. Garg, A. X. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I / A. X. Garg, W. F. Clark, R. B. Haynes, A. A. House // Kidney Int. – 2002. – Vol. 61. – P. 1486–1494.
5. Gibson, C. M. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality / C. M. Gibson, D. S. Pinto, S. A. Murphy et al. // J. Am. Coll. Cardiol. – 2003. – Vol. 42. – P. 1535–1543.
6. Go, A. S. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization / A. S. Go, G. M. Chertow, D. Fan et al. // N. Engl. J. Med. – 2004. – Vol. 351. – P. 1296–1305.
7. Goldberg, A. In-hospital and one-year mortality of patients who develop worsening renal function after acute ST-elevation myocardial infarction / A. Goldberg, H. Hammerman, S. Petcherski et al. // Circulation. – 2004. – Vol. 110. – P. III-391.
8. Jose, P. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction / P. Jose, H. Skali, N. Anavekar et al. // J. Am. Soc. Nephrol. – 2006. – Vol. 17. – P. 2886–2891.
9. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification // Am. J. Kidney Dis. – 2002. – Vol. 39 (Febr. Suppl. 1).
10. Keane, W. F. Renal protective effects of angiotensinconverting enzyme inhibition / W. F. Keane, B. E. Shapiro // Am. J. Cardiol. – 1990. – Vol. 65. – P. 49I–53.
11. Keith, D. S. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization / D. S. Keith, G. A. Nichols, C. M. Gullion et al. // Arch. Intern. Med. – 2004. – Vol. 164. – P. 659–663.
12. Marenzi, G. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty / G. Marenzi, M. Moltrasio, E. Assanelli et al. // Am. Heart J. – 2007. – Vol. 153. – P. 755–762.
13. Matsuda, H. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin / H. Matsuda, K. Hayashi, K. Arakawa // J. Am. Soc. Nephrol. – 1999. – Vol. 10. – P. 2272–2282.
14. Nohria, A. Cardiorenal interactions–insights form the ESCAPE trial / A. Nohria, V. Hasselblad, A. Stebbins et al. // J. Am. Coll. Cardiol. – 2007. – Vol. 51. – P. 1268–1274.
15. Ronco, C. Cardiorenal syndrome / C. Ronco, M. Haapio, A. A. House et al. // J. Am. Coll. Cardiol. – 2008. – Vol. 52. – P. 1527–1539.
16. Sarnak, M. J. Cardiovascular disease risk factors in chronic renal insufficiency / M. J. Sarnak, B. E. Coronado, T. Greene et al. // Clin. Nephrol. – 2002. – Vol. 57, № 5. – P. 327–335.
17. Sorensen, C. R. The prognostic importance of creatinine clearance after acute myocardial infarction / C. R. Sorensen, B. Brendorp, C. Rask-Madsen et al. // Eur. Heart J. – 2002. – Vol. 23. – P. 948–952.
18. Tokmakova, M. P. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study / M. P. Tokmakova, H. Skali, S. Kenchaiah et al. // Circulation. – 2004. – Vol. 110. – P. 3667–3673.
